Tango Therapeutics, Inc. SEC filings TNGX
Tango Therapeutics, Inc. has 424 filings in SEC EDGAR's recent list, going back to Jul 30, 2020. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Aug 11, 2026 | — |
| 424B5 | Prospectus supplement | Jun 10, 2026 | — |
| FWP | Free writing prospectus | Jun 10, 2026 | — |
| 424B5 | Prospectus supplement | Jun 8, 2026 | — |
| S-8 | Employee stock plan registration | Mar 5, 2026 | — |
| S-3ASR | Automatic shelf registration | Nov 21, 2025 | — |
| S-3 | Shelf registration | Nov 21, 2025 | — |
| 424B5 | Prospectus supplement | Oct 24, 2025 | — |
| FWP | Free writing prospectus | Oct 23, 2025 | — |
| S-3 | Shelf registration | May 12, 2025 | — |
| S-8 | Employee stock plan registration | Feb 27, 2025 | — |
| S-8 | Employee stock plan registration | Mar 18, 2024 | — |
| S-3 | Shelf registration | Sep 1, 2023 | — |
| S-8 | Employee stock plan registration | Feb 7, 2023 | — |
| POS AM | Filing | Sep 21, 2022 | — |
| S-3 | Shelf registration | Sep 1, 2022 | — |
| 424B3 | Prospectus | Aug 10, 2022 | — |
| 424B3 | Prospectus | Jun 10, 2022 | — |
| 424B3 | Prospectus | May 11, 2022 | — |
| POS AM | Filing | Mar 28, 2022 | — |
| S-8 | Employee stock plan registration | Mar 28, 2022 | — |
| 424B3 | Prospectus | Nov 9, 2021 | — |
| S-8 | Employee stock plan registration | Oct 14, 2021 | — |
| 424B3 | Prospectus | Oct 8, 2021 | — |
| 424B3 | Prospectus | Sep 29, 2021 | — |
| S-1 | Registration statement | Sep 10, 2021 | — |
| 424B3 | Prospectus | Jul 19, 2021 | — |
| S-4/A | Amendment no. 3 to form s-4 | Jul 16, 2021 | — |
| S-4/A | Amendment no. 2 to form s-4 | Jul 6, 2021 | — |
| S-4/A | Registration statement | Jun 17, 2021 | — |
| S-4 | Registration for a merger or exchange | Apr 20, 2021 | — |
| 424B4 | Prospectus | Sep 4, 2020 | — |
| S-1MEF | Registration statement | Sep 2, 2020 | — |
| S-1/A | Amended registration statement | Aug 31, 2020 | — |
| S-1 | Registration statement | Jul 30, 2020 | — |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1819133
- Former names
- BCTG Acquisition Corp. (until Aug 9, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.